JP2016537408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537408A5 JP2016537408A5 JP2016551077A JP2016551077A JP2016537408A5 JP 2016537408 A5 JP2016537408 A5 JP 2016537408A5 JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016537408 A5 JP2016537408 A5 JP 2016537408A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- composition
- calcium phosphate
- amorphous magnesium
- substituted calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 210
- 239000000203 mixture Substances 0.000 claims description 156
- -1 magnesium-substituted calcium phosphate Chemical class 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 40
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 22
- 239000011777 magnesium Substances 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 20
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 15
- 239000001506 calcium phosphate Substances 0.000 claims description 15
- 235000011010 calcium phosphates Nutrition 0.000 claims description 15
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002441 X-ray diffraction Methods 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 5
- 108010013639 Peptidoglycan Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000005004 lymphoid follicle Anatomy 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010061958 Food Intolerance Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000007997 Tricine buffer Substances 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007998 bicine buffer Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 210000001986 peyer's patch Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1319548.2 | 2013-11-05 | ||
| GBGB1319548.2A GB201319548D0 (en) | 2013-11-05 | 2013-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| PCT/GB2014/053291 WO2015067939A1 (en) | 2013-11-05 | 2014-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173127A Division JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016537408A JP2016537408A (ja) | 2016-12-01 |
| JP2016537408A5 true JP2016537408A5 (https=) | 2017-11-02 |
Family
ID=49767709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551077A Pending JP2016537408A (ja) | 2013-11-05 | 2014-11-05 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
| JP2019173127A Withdrawn JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173127A Withdrawn JP2020073467A (ja) | 2013-11-05 | 2019-09-24 | 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10596122B2 (https=) |
| EP (1) | EP3065715B1 (https=) |
| JP (2) | JP2016537408A (https=) |
| KR (1) | KR20160079060A (https=) |
| CN (1) | CN105722504A (https=) |
| AU (1) | AU2014345334B2 (https=) |
| BR (1) | BR112016009809A2 (https=) |
| CA (1) | CA2929123A1 (https=) |
| EA (1) | EA201690659A1 (https=) |
| ES (1) | ES2761559T3 (https=) |
| GB (1) | GB201319548D0 (https=) |
| IL (1) | IL245380B (https=) |
| MX (1) | MX367473B (https=) |
| SG (2) | SG10201803562YA (https=) |
| WO (1) | WO2015067939A1 (https=) |
| ZA (1) | ZA201602906B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| FR3021045B1 (fr) * | 2014-05-16 | 2020-02-21 | Solvay Sa | Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation |
| KR101893110B1 (ko) * | 2016-07-27 | 2018-08-31 | 삼일제약 주식회사 | 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제 |
| EP3538659A4 (en) * | 2016-11-09 | 2020-07-15 | Engene, Inc. | INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1 |
| CN110573455A (zh) * | 2017-04-27 | 2019-12-13 | 武礼伟仁株式会社 | 羟基磷灰石、化妆品和食品及其生产方法 |
| CN111417459B (zh) * | 2019-07-05 | 2020-12-29 | 广州中大医疗器械有限公司 | 一种可载药微球及其制备方法 |
| CN114615966B (zh) | 2019-10-30 | 2025-10-10 | 皮斯洛克斯有限公司 | 稳定的非晶态钙镁磷酸盐颗粒组合物 |
| CN116768175B (zh) * | 2023-07-01 | 2025-12-19 | 常州市第二人民医院 | 高稳定性生物活性无定形磷酸钙镁的制备方法及应用 |
| CN118929595A (zh) * | 2024-08-30 | 2024-11-12 | 昆明理工大学 | 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| US6541037B1 (en) * | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| JP5097540B2 (ja) | 2005-04-06 | 2012-12-12 | 株式会社サンギ | 腸管吸収用抗腫瘍剤 |
| CN101557720B (zh) | 2006-12-12 | 2013-05-29 | 弗门尼舍有限公司 | 具有无定形金属盐作为载体的活性成分递送系统 |
| WO2009135190A2 (en) * | 2008-05-01 | 2009-11-05 | Nod Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of making and using same |
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
-
2013
- 2013-11-05 GB GBGB1319548.2A patent/GB201319548D0/en not_active Ceased
-
2014
- 2014-11-05 EP EP14799845.4A patent/EP3065715B1/en not_active Not-in-force
- 2014-11-05 JP JP2016551077A patent/JP2016537408A/ja active Pending
- 2014-11-05 BR BR112016009809A patent/BR112016009809A2/pt not_active Application Discontinuation
- 2014-11-05 US US15/033,750 patent/US10596122B2/en not_active Expired - Fee Related
- 2014-11-05 SG SG10201803562YA patent/SG10201803562YA/en unknown
- 2014-11-05 MX MX2016005415A patent/MX367473B/es active IP Right Grant
- 2014-11-05 AU AU2014345334A patent/AU2014345334B2/en not_active Ceased
- 2014-11-05 ES ES14799845T patent/ES2761559T3/es active Active
- 2014-11-05 WO PCT/GB2014/053291 patent/WO2015067939A1/en not_active Ceased
- 2014-11-05 CN CN201480060734.7A patent/CN105722504A/zh active Pending
- 2014-11-05 CA CA2929123A patent/CA2929123A1/en not_active Abandoned
- 2014-11-05 EA EA201690659A patent/EA201690659A1/ru unknown
- 2014-11-05 SG SG11201603261PA patent/SG11201603261PA/en unknown
- 2014-11-05 KR KR1020167014309A patent/KR20160079060A/ko not_active Ceased
-
2016
- 2016-04-29 ZA ZA2016/02906A patent/ZA201602906B/en unknown
- 2016-05-01 IL IL245380A patent/IL245380B/en not_active IP Right Cessation
-
2019
- 2019-09-24 JP JP2019173127A patent/JP2020073467A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537408A5 (https=) | ||
| Chew et al. | Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice | |
| Han et al. | Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development | |
| Lee et al. | Biodegradable viral nanoparticle/polymer implants prepared via melt-processing | |
| JP2020172501A (ja) | 炎症の治療のための免疫修飾粒子 | |
| JP2023134731A (ja) | 特異的ａｋｔ３活性化剤およびその使用 | |
| Doostmohammadi et al. | Hydrogels for peptide hormones delivery: therapeutic and tissue engineering applications | |
| CN102083419A (zh) | 包含表面被覆了的微粒的医药组合物 | |
| RU2011115192A (ru) | Диетологическая поддержка иммунной системы во время противораковой терапии | |
| JP2006020648A5 (https=) | ||
| JP2020528744A5 (https=) | ||
| CN108351687A (zh) | 靶向胰腺和结肠的聚合胆汁酸纳米组合物 | |
| US10786558B2 (en) | Oral dissolving films | |
| US10596122B2 (en) | Amorphous magnesium-substituted calcium phosphate compositions and their uses | |
| US20220211636A1 (en) | Microparticles and nanoparticles having negative surface charges | |
| EP3220913B1 (en) | Nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies | |
| Okay et al. | Nanoparticle-based delivery platforms for mRNA vaccine development | |
| CN110769862B (zh) | 包含脂肽(lp)化合物的非病毒基因递送剂 | |
| Hanafi et al. | Cellulose acetate phthalate microencapsulation and delivery of plasmid DNA to the intestines | |
| Thirumalaikumar et al. | DNA vaccine incorporated poly (lactic-co-glycolic) acid (PLGA) microspheres offer enhanced protection against Aeromonas hydrophila infection | |
| CN114288398A (zh) | 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用 | |
| CN110882232B (zh) | 一种基于微囊的疫苗 | |
| US10849962B2 (en) | Method and apparatus for microneedle transdermal delivery | |
| JP3492671B2 (ja) | 免疫アジュバント | |
| RU2815372C2 (ru) | Специфический активатор akt3 и его применение |